Skip to Content
Merck
CN
  • The efficacy of bromides, stiripentol and levetiracetam in two patients with malignant migrating partial seizures in infancy.

The efficacy of bromides, stiripentol and levetiracetam in two patients with malignant migrating partial seizures in infancy.

Epileptic disorders : international epilepsy journal with videotape (2011-03-12)
Milena Djuric, Ruzica Kravljanac, Gordana Kovacevic, Jelena Martic
ABSTRACT

The syndrome of malignant migrating partial seizures in infancy is a devastating, age-specific, epileptic encephalopathy, which still presents an aetiological, pathophysiological and therapeutic problem. In this study, we present two patients who were diagnosed with the disease, based on electroclinical symptoms. The patients were treated with a combination of sodium bromide, stiripentol and levetiracetam. The first patient unequivocally responded, following a course of ineffective conventional drugs, and the second, who was diagnosed and treated immediately, showed a more significant therapeutic response. Antiepileptic drugs, previously reported to be beneficial in case reports, when given concomitantly, may substantially reduce the number and severity of seizures, without influence on psychomotor development. [Published with video sequences].

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium bromide, ReagentPlus®, ≥99%
Sigma-Aldrich
Sodium bromide, ACS reagent, ≥99.0%
Sigma-Aldrich
Stiripentol, ≥98% (HPLC)
Supelco
Density Standard 1251 kg/m3, H&D Fitzgerald Ltd. Quality
Sigma-Aldrich
Sodium bromide, Vetec, reagent grade, 98%
Sigma-Aldrich
Sodium bromide, BioXtra, ≥99.0%
Sigma-Aldrich
Sodium bromide, BioUltra, ≥99.0% (AT)
Sigma-Aldrich
Sodium bromide, ≥99.99% trace metals basis